Cargando…

Targeted Protein Degradation: Advances, Challenges, and Prospects for Computational Methods

[Image: see text] The therapeutic approach of targeted protein degradation (TPD) is gaining momentum due to its potentially superior effects compared with protein inhibition. Recent advancements in the biotech and pharmaceutical sectors have led to the development of compounds that are currently in...

Descripción completa

Detalles Bibliográficos
Autores principales: Mostofian, Barmak, Martin, Holli-Joi, Razavi, Asghar, Patel, Shivam, Allen, Bryce, Sherman, Woody, Izaguirre, Jesus A
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Chemical Society 2023
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10498452/
https://www.ncbi.nlm.nih.gov/pubmed/37602861
http://dx.doi.org/10.1021/acs.jcim.3c00603
_version_ 1785105522586812416
author Mostofian, Barmak
Martin, Holli-Joi
Razavi, Asghar
Patel, Shivam
Allen, Bryce
Sherman, Woody
Izaguirre, Jesus A
author_facet Mostofian, Barmak
Martin, Holli-Joi
Razavi, Asghar
Patel, Shivam
Allen, Bryce
Sherman, Woody
Izaguirre, Jesus A
author_sort Mostofian, Barmak
collection PubMed
description [Image: see text] The therapeutic approach of targeted protein degradation (TPD) is gaining momentum due to its potentially superior effects compared with protein inhibition. Recent advancements in the biotech and pharmaceutical sectors have led to the development of compounds that are currently in human trials, with some showing promising clinical results. However, the use of computational tools in TPD is still limited, as it has distinct characteristics compared with traditional computational drug design methods. TPD involves creating a ternary structure (protein–degrader–ligase) responsible for the biological function, such as ubiquitination and subsequent proteasomal degradation, which depends on the spatial orientation of the protein of interest (POI) relative to E2-loaded ubiquitin. Modeling this structure necessitates a unique blend of tools initially developed for small molecules (e.g., docking) and biologics (e.g., protein–protein interaction modeling). Additionally, degrader molecules, particularly heterobifunctional degraders, are generally larger than conventional small molecule drugs, leading to challenges in determining drug-like properties like solubility and permeability. Furthermore, the catalytic nature of TPD makes occupancy-based modeling insufficient. TPD consists of multiple interconnected yet distinct steps, such as POI binding, E3 ligase binding, ternary structure interactions, ubiquitination, and degradation, along with traditional small molecule properties. A comprehensive set of tools is needed to address the dynamic nature of the induced proximity ternary complex and its implications for ubiquitination. In this Perspective, we discuss the current state of computational tools for TPD. We start by describing the series of steps involved in the degradation process and the experimental methods used to characterize them. Then, we delve into a detailed analysis of the computational tools employed in TPD. We also present an integrative approach that has proven successful for degrader design and its impact on project decisions. Finally, we examine the future prospects of computational methods in TPD and the areas with the greatest potential for impact.
format Online
Article
Text
id pubmed-10498452
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher American Chemical Society
record_format MEDLINE/PubMed
spelling pubmed-104984522023-09-14 Targeted Protein Degradation: Advances, Challenges, and Prospects for Computational Methods Mostofian, Barmak Martin, Holli-Joi Razavi, Asghar Patel, Shivam Allen, Bryce Sherman, Woody Izaguirre, Jesus A J Chem Inf Model [Image: see text] The therapeutic approach of targeted protein degradation (TPD) is gaining momentum due to its potentially superior effects compared with protein inhibition. Recent advancements in the biotech and pharmaceutical sectors have led to the development of compounds that are currently in human trials, with some showing promising clinical results. However, the use of computational tools in TPD is still limited, as it has distinct characteristics compared with traditional computational drug design methods. TPD involves creating a ternary structure (protein–degrader–ligase) responsible for the biological function, such as ubiquitination and subsequent proteasomal degradation, which depends on the spatial orientation of the protein of interest (POI) relative to E2-loaded ubiquitin. Modeling this structure necessitates a unique blend of tools initially developed for small molecules (e.g., docking) and biologics (e.g., protein–protein interaction modeling). Additionally, degrader molecules, particularly heterobifunctional degraders, are generally larger than conventional small molecule drugs, leading to challenges in determining drug-like properties like solubility and permeability. Furthermore, the catalytic nature of TPD makes occupancy-based modeling insufficient. TPD consists of multiple interconnected yet distinct steps, such as POI binding, E3 ligase binding, ternary structure interactions, ubiquitination, and degradation, along with traditional small molecule properties. A comprehensive set of tools is needed to address the dynamic nature of the induced proximity ternary complex and its implications for ubiquitination. In this Perspective, we discuss the current state of computational tools for TPD. We start by describing the series of steps involved in the degradation process and the experimental methods used to characterize them. Then, we delve into a detailed analysis of the computational tools employed in TPD. We also present an integrative approach that has proven successful for degrader design and its impact on project decisions. Finally, we examine the future prospects of computational methods in TPD and the areas with the greatest potential for impact. American Chemical Society 2023-08-21 /pmc/articles/PMC10498452/ /pubmed/37602861 http://dx.doi.org/10.1021/acs.jcim.3c00603 Text en © 2023 American Chemical Society https://creativecommons.org/licenses/by/4.0/Permits the broadest form of re-use including for commercial purposes, provided that author attribution and integrity are maintained (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Mostofian, Barmak
Martin, Holli-Joi
Razavi, Asghar
Patel, Shivam
Allen, Bryce
Sherman, Woody
Izaguirre, Jesus A
Targeted Protein Degradation: Advances, Challenges, and Prospects for Computational Methods
title Targeted Protein Degradation: Advances, Challenges, and Prospects for Computational Methods
title_full Targeted Protein Degradation: Advances, Challenges, and Prospects for Computational Methods
title_fullStr Targeted Protein Degradation: Advances, Challenges, and Prospects for Computational Methods
title_full_unstemmed Targeted Protein Degradation: Advances, Challenges, and Prospects for Computational Methods
title_short Targeted Protein Degradation: Advances, Challenges, and Prospects for Computational Methods
title_sort targeted protein degradation: advances, challenges, and prospects for computational methods
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10498452/
https://www.ncbi.nlm.nih.gov/pubmed/37602861
http://dx.doi.org/10.1021/acs.jcim.3c00603
work_keys_str_mv AT mostofianbarmak targetedproteindegradationadvanceschallengesandprospectsforcomputationalmethods
AT martinhollijoi targetedproteindegradationadvanceschallengesandprospectsforcomputationalmethods
AT razaviasghar targetedproteindegradationadvanceschallengesandprospectsforcomputationalmethods
AT patelshivam targetedproteindegradationadvanceschallengesandprospectsforcomputationalmethods
AT allenbryce targetedproteindegradationadvanceschallengesandprospectsforcomputationalmethods
AT shermanwoody targetedproteindegradationadvanceschallengesandprospectsforcomputationalmethods
AT izaguirrejesusa targetedproteindegradationadvanceschallengesandprospectsforcomputationalmethods